Background: Anaplastic Lymphoma Kinase (ALK) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of ALK inhibitors in advanced DTCs. Methods: We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma. STRN – ALK translocation was detected by NGS – RNA analysis. Results: A 74-year-old woman received first line alectinib for the treatment of a STRN - ALK translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations. The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit. Conclusion: Here we report the first case in Europe of STRN - ALK translocated advanced thyroid carcinoma successfully treated with alectinib.
Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN – ALK fusion
Buriolla S.;Zapelloni G.;Pelizzari G.;Cortiula F.
2025-01-01
Abstract
Background: Anaplastic Lymphoma Kinase (ALK) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of ALK inhibitors in advanced DTCs. Methods: We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma. STRN – ALK translocation was detected by NGS – RNA analysis. Results: A 74-year-old woman received first line alectinib for the treatment of a STRN - ALK translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations. The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit. Conclusion: Here we report the first case in Europe of STRN - ALK translocated advanced thyroid carcinoma successfully treated with alectinib.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
